Results 21 to 30 of about 143,207 (265)
Безопасность и риск фармакотерапии, 2019 New oral anticoagulants are effective for the prevention of thromboembolic complications in patients with atrial fibrillation, or after orthopedic surgery.
A. P. Pereverzev +3 more
doaj +1 more source
Anti-Inflammatory and Anticancer Effects of Anticoagulant Therapy in Patients with Malignancy
Life, 2023 Optimizing the anticoagulation therapy is of pivotal importance in patients with a malignant tumor, as venous thromboembolism (VTE) has become the second-leading cause of death in this population.
Vincenzo Russo +10 more
doaj +1 more source
Animals, 2021 PIVKA-II is an aberrant form of vitamin K that has been demonstrated to be increased in human coagulation disorders and in some neoplastic diseases.
Lorella Maniscalco +8 more
doaj +1 more source
Impact of Alteplase on Mortality in Critically Ill Patients with COVID-19 and Pulmonary Embolism
Viruses, 2023 COVID-19 is an independent risk factor for pulmonary embolism (PE). Little is known about alteplase therapy in this patient group. A retrospective study analyzed 74 patients with PE and acute respiratory distress syndrome (ARDS) due to COVID-19 who were ...
Oleksandr Valentynovych Oliynyk +9 more
doaj +1 more source
Biology, 2022 Oral squamous cell carcinoma (OSCC) is the most common head and neck cancer. With anticoagulant usage on the rise, it is important to elucidate their potential effects on tumour biology and interactions with chemotherapeutics.
Li-Qiao R. Ling +6 more
doaj +1 more source
, 2022 Gastrointestinal bleeding (GIB) associated with the use of direct oral anticoagulants or, as they are also called, new oral anticoagulants (NOAC) is a serious medical problem, the relevance of which will only increase taking into account the constant ...
Natalya M. Vorobyeva +3 more
core +1 more source
Is the time in therapeutic range on coumarins predicted by previous time in therapeutic range?
Research and Practice in Thrombosis and Haemostasis, 2020 Background The benefit of vitamin K antagonists depends on the time within the therapeutic range (TTR). A patient’s previous TTR could be a factor in the decision to change the anticoagulation regimen.
Jasper H. A. vanMiert +2 more
doaj +1 more source
Low Exposure to Direct Oral Anticoagulants Is Associated with Ischemic Stroke and Its Severity [PDF]
Journal of Stroke, 2022 Background and purpose In acute stroke patients, plasma concentrations of direct oral anticoagulants (DOAC) at hospital admission only poorly mirror DOAC exposure or the coagulation status at the time of the event.
Timolaos Rizos +10 more
doaj +1 more source
Mechanical thrombextraction in patient with acute ischemic stroke on background of oral anticoagulant therapy [PDF]
Кардіохірургія та інтервенційна кардіологія, 2021 Thrombolytic therapy, which is a priority treatment strategy in patients with acute ischemic stroke in the first 3-4.5 hours after start of the disease, has significant limitations in case of background anticoagulant therapy. Mechanic thrombextraction is
V.О. Yarosh +5 more
doaj +1 more source
Oral anticoagulants: Optimizing venous thromboembolism management
Journal of Applied Hematology, 2019 A decade ago, oral anticoagulants were limited to Vitamin K antagonists, i.e., warfarin. Since 2010, the US Food and Drug Administration has approved several non-Vitamin K oral anticoagulants: dabigatran is a direct thrombin inhibitor, while apixaban ...
Fahad A S. Aleidan
doaj +1 more source